Hypoglycemic Effect of Combined Ghrelin and Glucagon Receptor Blockade.
Ontology highlight
ABSTRACT: Glucagon receptor (GcgR) blockade has been proposed as an alternative to insulin monotherapy for treating type 1 diabetes since deletion or inhibition of GcgRs corrects hyperglycemia in models of diabetes. The factors regulating glycemia in a setting devoid of insulin and glucagon function remain unclear but may include the hormone ghrelin. Not only is ghrelin release controlled by glucose but also ghrelin has many actions that can raise or reduce falls in blood glucose level. Here, we tested the hypothesis that ghrelin rises to prevent hypoglycemia in the absence of glucagon function. Both GcgR knockout (Gcgr-/-) mice and db/db mice that were administered GcgR monoclonal antibody displayed lower blood glucose levels accompanied by elevated plasma ghrelin le
SUBMITTER: Mani BK
PROVIDER: S-EPMC5482080 | biostudies-literature | 2017 Jul
REPOSITORIES: biostudies-literature
ACCESS DATA